Innate Pharma (IPH.PA) Stock Price

Innate Pharma Price

Euronext·CLOSED
1.59EUR+0.0040 (+0.25 %)
Market closed

Revenue at Innate Pharma has contracted by 4.1% per year over the past 19 years to 2.79 M EUR. For Innate Pharma, the net margin of -1,764.5% is down versus -436.0% a few years ago. The consensus 12-month price target for Innate Pharma is 6.27 EUR, about 295.0% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 50% above its 52-week low.

Innate Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Innate Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Innate Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Innate Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Innate Pharma Stock Price History
DateInnate Pharma Price
7/24/20261.59 EUR
7/23/20261.58 EUR
7/22/20261.56 EUR
7/21/20261.55 EUR
7/20/20261.50 EUR
7/17/20261.51 EUR
7/16/20261.56 EUR
7/15/20261.58 EUR
7/14/20261.59 EUR
7/13/20261.61 EUR
7/10/20261.57 EUR
7/9/20261.59 EUR
7/8/20261.59 EUR
7/7/20261.66 EUR
7/6/20261.71 EUR
7/3/20261.65 EUR
7/2/20261.60 EUR
7/1/20261.59 EUR
6/30/20261.62 EUR
6/29/20261.60 EUR
6/26/20261.58 EUR
6/25/20261.59 EUR
6/24/20261.66 EUR
6/23/20261.68 EUR
6/22/20261.61 EUR
6/19/20261.61 EUR
6/18/20261.60 EUR
6/17/20261.58 EUR
6/16/20261.55 EUR
6/15/20261.60 EUR
6/12/20261.56 EUR
6/11/20261.55 EUR
6/10/20261.54 EUR
6/9/20261.54 EUR
6/8/20261.55 EUR
6/5/20261.54 EUR
6/4/20261.55 EUR
6/3/20261.54 EUR
6/2/20261.57 EUR
6/1/20261.58 EUR
5/29/20261.61 EUR
5/28/20261.50 EUR
5/27/20261.54 EUR
5/26/20261.55 EUR
5/25/20261.61 EUR
5/22/20261.64 EUR
5/21/20261.80 EUR
5/20/20261.96 EUR
5/19/20261.81 EUR
5/18/20261.95 EUR
5/15/20261.74 EUR
5/14/20261.66 EUR
5/13/20261.23 EUR
5/12/20261.25 EUR
5/11/20261.26 EUR
5/8/20261.25 EUR
5/7/20261.26 EUR
5/6/20261.27 EUR
5/5/20261.23 EUR
5/4/20261.25 EUR
4/30/20261.20 EUR
4/29/20261.19 EUR
4/28/20261.18 EUR
4/27/20261.16 EUR
4/24/20261.12 EUR
4/23/20261.15 EUR
4/22/20261.18 EUR
4/21/20261.26 EUR
4/20/20261.30 EUR
4/17/20261.38 EUR
4/16/20261.35 EUR
4/15/20261.41 EUR
4/14/20261.36 EUR
4/13/20261.20 EUR
4/10/20261.16 EUR
4/9/20261.17 EUR
4/8/20261.19 EUR
4/7/20261.10 EUR
4/2/20261.16 EUR
4/1/20261.12 EUR
3/31/20261.06 EUR
3/30/20261.08 EUR
3/27/20261.10 EUR
3/26/20261.08 EUR
3/25/20261.15 EUR
3/24/20261.13 EUR
3/23/20261.17 EUR
3/20/20261.07 EUR
3/19/20261.15 EUR
3/18/20261.18 EUR
3/17/20261.17 EUR
3/16/20261.23 EUR
3/13/20261.25 EUR
3/12/20261.27 EUR
3/11/20261.35 EUR
3/10/20261.40 EUR
3/9/20261.38 EUR
3/6/20261.39 EUR
3/5/20261.37 EUR
3/4/20261.40 EUR
3/3/20261.37 EUR
3/2/20261.44 EUR
2/27/20261.46 EUR
2/26/20261.50 EUR
2/25/20261.49 EUR
2/24/20261.49 EUR
2/23/20261.41 EUR
2/20/20261.41 EUR
2/19/20261.45 EUR
2/18/20261.45 EUR
2/17/20261.44 EUR
2/16/20261.45 EUR
2/13/20261.47 EUR
2/12/20261.41 EUR
2/11/20261.40 EUR
2/10/20261.43 EUR
2/9/20261.40 EUR
2/6/20261.43 EUR
2/5/20261.49 EUR
2/4/20261.52 EUR
2/3/20261.52 EUR
2/2/20261.55 EUR
1/30/20261.55 EUR
1/29/20261.55 EUR
1/28/20261.51 EUR
1/27/20261.49 EUR
1/26/20261.50 EUR
1/23/20261.53 EUR
1/22/20261.56 EUR
1/21/20261.48 EUR
1/20/20261.52 EUR
1/19/20261.50 EUR
1/16/20261.51 EUR
1/15/20261.50 EUR
1/14/20261.51 EUR
1/13/20261.52 EUR
1/12/20261.55 EUR
1/9/20261.52 EUR
1/8/20261.53 EUR
1/7/20261.56 EUR
1/6/20261.55 EUR
1/5/20261.56 EUR
1/2/20261.62 EUR
12/31/20251.60 EUR
12/30/20251.61 EUR
12/29/20251.54 EUR
12/24/20251.55 EUR
12/23/20251.52 EUR
12/22/20251.56 EUR
12/19/20251.53 EUR
12/18/20251.55 EUR
12/17/20251.57 EUR
12/16/20251.61 EUR
12/15/20251.62 EUR
12/12/20251.63 EUR
12/11/20251.67 EUR
12/10/20251.64 EUR
12/9/20251.64 EUR
12/8/20251.66 EUR
12/5/20251.67 EUR
12/4/20251.68 EUR
12/3/20251.71 EUR
12/2/20251.74 EUR
12/1/20251.73 EUR
11/28/20251.75 EUR
11/27/20251.71 EUR
11/26/20251.66 EUR
11/25/20251.67 EUR
11/24/20251.64 EUR
11/21/20251.62 EUR
11/20/20251.60 EUR
11/19/20251.59 EUR
11/18/20251.55 EUR
11/17/20251.57 EUR
11/14/20251.59 EUR
11/13/20251.61 EUR
11/12/20251.66 EUR
11/11/20251.71 EUR
11/10/20251.87 EUR
11/7/20251.52 EUR
11/6/20251.51 EUR
11/5/20251.57 EUR
11/4/20251.61 EUR
11/3/20251.64 EUR
10/31/20251.67 EUR
10/30/20251.70 EUR
10/29/20251.73 EUR
10/28/20251.69 EUR
10/27/20251.89 EUR
10/24/20251.85 EUR
10/23/20251.82 EUR
10/22/20251.81 EUR
10/21/20251.80 EUR
10/20/20251.79 EUR
10/17/20251.84 EUR
10/16/20251.95 EUR
10/15/20251.87 EUR
10/14/20251.81 EUR
10/13/20251.68 EUR
10/10/20251.70 EUR
10/9/20251.81 EUR
10/8/20251.78 EUR
10/7/20251.73 EUR
10/6/20251.77 EUR
10/3/20251.82 EUR
10/2/20251.75 EUR
10/1/20251.74 EUR
9/30/20251.71 EUR
9/29/20251.64 EUR
9/26/20251.62 EUR
9/25/20251.62 EUR
9/24/20251.62 EUR
9/23/20251.59 EUR
9/22/20251.58 EUR
9/19/20251.58 EUR
9/18/20251.67 EUR
9/17/20251.76 EUR
9/16/20251.79 EUR
9/15/20251.82 EUR
9/12/20251.72 EUR
9/11/20251.77 EUR
9/10/20251.78 EUR
9/9/20251.77 EUR
9/8/20251.75 EUR
9/5/20251.77 EUR
9/4/20251.84 EUR
9/3/20251.86 EUR
9/2/20251.84 EUR
9/1/20251.88 EUR
8/29/20251.84 EUR
8/28/20251.86 EUR
8/27/20251.84 EUR
8/26/20251.86 EUR
8/25/20251.95 EUR
8/22/20252.01 EUR
8/21/20251.97 EUR
8/20/20251.98 EUR
8/19/20252.02 EUR
8/18/20251.99 EUR
8/15/20251.96 EUR
8/14/20251.93 EUR
8/13/20251.90 EUR
8/12/20251.81 EUR
8/11/20251.82 EUR
8/8/20251.83 EUR
8/7/20251.83 EUR
8/6/20251.83 EUR
8/5/20251.85 EUR
8/4/20251.85 EUR
8/1/20251.86 EUR
7/31/20251.87 EUR
7/30/20251.93 EUR
7/29/20251.92 EUR
7/28/20251.91 EUR
Access this data via the Eulerpool API
Get Free API Key

Innate Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
51.90 M EUR
-12.67 M EUR
-7.57 M EUR
Jan 1, 2024
12.62 M EUR
-51.58 M EUR
-49.47 M EUR
Jan 1, 2025
2.79 M EUR
-53.43 M EUR
-49.18 M EUR
Jan 1, 2026 (e)
31.21 M EUR
22.38 M EUR
77.00 M EUR
Jan 1, 2027 (e)
64.75 M EUR
-28.83 M EUR
174.26 M EUR
Jan 1, 2028 (e)
80.73 M EUR
-65.42 M EUR
0.00 EUR
Jan 1, 2029 (e)
199.83 M EUR
41.24 M EUR
0.00 EUR
Jan 1, 2030 (e)
255.40 M EUR
64.20 M EUR
0.00 EUR

Innate Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 27, 2026, 12:08 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
10.0012.00–17.0056.0032.0079.0068.0069.0012.0057.0051.0012.002.0031.0064.00
-9.0920.00––229.41-42.86146.88-13.921.47-82.61375.00-10.53-76.47-83.331,450.00106.45
30.0033.33–-70.5912.50-106.2512.6633.8228.99-183.3310.539.80100.00100.00100.00100.00
3.004.00-11.00-12.007.00-34.0010.0023.0020.00-22.006.005.0012.002.0031.0064.00
-3.00-2.00-19.00-10.007.00-47.005.00-27.001.00-47.00-57.00-12.00-51.00-53.0022.00-28.00
-30.00-16.67–-58.8212.50-146.886.33-39.711.45-391.67-100.00-23.53-425.00-2,650.0070.97-43.75
-3.00-2.00-19.00-6.0012.00-48.003.00-20.00-63.00-52.00-58.00-7.00-49.00-49.0076.00174.00
-50.00-33.33850.00-68.42-300.00-500.00-106.25-766.67215.00-17.4611.54-87.93600.00–-255.10128.95
37.9239.4052.9753.6455.3354.7559.9565.7478.9979.5280.1980.5981.2591.4191.4191.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Innate Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Innate Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Innate Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Innate Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Innate Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-184.12 %
-394.86 %
-436.01 %
Jan 1, 2022
10.42 %
-100.02 %
-100.74 %
Jan 1, 2023
10.83 %
-24.41 %
-14.59 %
Jan 1, 2024
100.00 %
-408.64 %
-391.97 %
Jan 1, 2025
100.00 %
-1,916.94 %
-1,764.51 %
Jan 1, 2026 (e)
100.00 %
71.70 %
246.68 %
Jan 1, 2027 (e)
100.00 %
-44.53 %
269.14 %
Jan 1, 2028 (e)
100.00 %
-81.04 %
0.00 %

Innate Pharma Stock Revenue, EBIT, Earnings per Share

The Innate Pharma earnings per share therefore indicates how much revenue Innate Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.15 EUR
-0.60 EUR
-0.66 EUR
Jan 1, 2022
0.72 EUR
-0.72 EUR
-0.72 EUR
Jan 1, 2023
0.64 EUR
-0.16 EUR
-0.09 EUR
Jan 1, 2024
0.16 EUR
-0.63 EUR
-0.61 EUR
Jan 1, 2025
0.03 EUR
-0.58 EUR
-0.54 EUR
Jan 1, 2026 (e)
0.39 EUR
0.24 EUR
0.95 EUR
Jan 1, 2027 (e)
0.80 EUR
-0.32 EUR
2.15 EUR
Jan 1, 2028 (e)
1.00 EUR
-0.72 EUR
0.00 EUR

Innate Pharma business model & stock analysis

The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company.

Innate Pharma SWOT Analysis

Strengths

1. Strong portfolio of innovative drug candidates.

2. Collaborative partnerships with renowned pharmaceutical companies.

3. Expertise in immuno-oncology, a rapidly growing field.

4. Solid financial position and resources for research and development.

Weaknesses

1. Limited commercialized products and dependence on partnerships.

2. Reliance on successful clinical trials for revenue generation.

3. Vulnerability to changes in regulations or intellectual property rights.

4. Lack of global market presence compared to larger pharmaceutical companies.

Opportunities

1. Rising demand for immunotherapies and targeted treatment options.

2. Potential for expansion into emerging markets with unmet medical needs.

3. Possibility of strategic partnerships for further drug development.

4. Increasing focus on personalized medicine and precision therapies.

Threats

1. Intense competition in the immuno-oncology sector.

2. Regulatory hurdles and approval challenges for new drugs.

3. Pricing pressures and reimbursement uncertainties.

4. Potential for disruptive technologies to replace current treatment approaches.

Innate Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Innate Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Innate Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Innate Pharma shares outstanding

The number of shares of Innate Pharma was 91.41 M in 2025. This indicates how many shares Innate Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
79.52 M Stocks
Jan 1, 2022
80.19 M Stocks
Jan 1, 2023
80.59 M Stocks
Jan 1, 2024
81.25 M Stocks
Jan 1, 2025
91.41 M Stocks
Jan 1, 2026 (e)
91.41 M Stocks
Jan 1, 2027 (e)
91.41 M Stocks
Jan 1, 2028 (e)
91.41 M Stocks

Current Innate Pharma forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy87.50 % (7)
Hold12.50 % (1)
Sell0.00 % (0)
12M Price Target
6.27
Last Price
1.59
Currency
EUR
12M Return Potential
295.03 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Innate Pharma stock

53/100
58
Environment
49
Social
51
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Innate Pharma shareholder structure

% Name
11.33935%
Novo Nordisk Foundation
Novo Nordisk Foundation
10.29636%
Sanofi SA
Sanofi SA
9.23545%
AstraZeneca PLC
AstraZeneca PLC
9.03056%
Caisse des Dépôts et Consignations
Caisse des Dépôts et Consignations
1.99554%
Innate Pharma SA Employees
Innate Pharma SA Employees
0.96276%
Platinum Asset Management
Platinum Asset Management

Innate Pharma Executives and Management Board

SQ

Dr. Sonia Quaratino

(62)

Executive Vice President, Member of the Executive Board, Chief Medical Officer, Member of the Leadership Team

Compensation770,500.00 EUR
YM

Mr. Yannis Morel

(51)

Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team

Compensation709,792.00 EUR
JD

Mr. Jonathan Dickinson

(57)

Chief Executive Officer, Member of the Leadership Team

Compensation435,249.00 EUR
IS

Dr. Irina Staatz-Granzer

(65)

Chairwoman of the Board of Directors · since 2009

Compensation100,000.00 EUR
PB

Ms. Pascale Boissel

(58)

Independent Vice Chairwoman of the Supervisory Board · since 2020

Compensation64,000.00 EUR

Frequently asked questions about Innate Pharma

The business model of Innate Pharma SA is centered around the development and commercialization of innovative immunotherapies for the treatment of cancer and inflammatory diseases. Innate Pharma combines cutting-edge expertise in immunology with advanced technology platforms to discover and develop first-in-class antibodies targeting receptors and pathways controlling the activation and regulation of the immune system. By leveraging its scientific know-how and strategic partnerships, Innate Pharma aims to bring novel immunotherapies to patients, addressing unmet medical needs and potentially improving outcomes. Innate Pharma SA focuses on research, development, and collaboration to advance its pipeline and ultimately deliver breakthrough therapies.

All fundamentals and in-depth analysis of Innate Pharma

Our stock analysis for Innate Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Innate Pharma Stock
Innate Pharma Revenue→
Innate Pharma Stock
Innate Pharma Net Income→
Innate Pharma Stock
Innate Pharma P/E→
Innate Pharma Stock
Innate Pharma P/S→
Innate Pharma Stock
Innate Pharma EBIT→
Innate Pharma Stock
Innate Pharma Dividend→
Innate Pharma Stock
Innate Pharma Directors Dealings→
Innate Pharma Stock
Innate Pharma Stocks→
Innate Pharma Stock
Innate Pharma Market capitalization→
Innate Pharma Stock
Innate Pharma Debt→
Innate Pharma Stock
Innate Pharma Liabilities→
Innate Pharma Stock
Innate Pharma Equity→
Innate Pharma Stock
Innate Pharma AAQS→
Innate Pharma Stock
Innate Pharma Employees→
Innate Pharma Stock
Innate Pharma ROE→
Innate Pharma Stock
Innate Pharma ROA→
Innate Pharma Stock
Innate Pharma ROCE→
Innate Pharma Stock
Innate Pharma News→
Innate Pharma Stock
Innate Pharma Analyst Price Targets→

Health Stocks

Inner Mongolia Furui Medical Science CoInnate PharmaInnoCare PharmaINmune BioInnoCare PharmaInmodeInnopharmaxInMed PharmaceuticalsInnova CaptabINKON Life Technology CoInnovAge HoldingInitiator Pharma A/SAll Stocks A–Z →